Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant TAC chemotherapy with or without zoledronic acid in HER2-negative breast cancer
2009-016932-11Phase 3Active
- Sponsor
- Borstkanker Onderzoek Groep
- Start
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of zoledronic acid in breast cancer (2 arms), sponsored by Borstkanker Onderzoek Groep. Primary endpoint: Pathologic complete response at surgery. Started Jan 2010; status: active.
02
Drugs
zoledronic acid
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2009-016932-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016932-11.